Marizyme Company Description
Marizyme, Inc., a multi-technology Life Science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia.
The company operates as a medical technology company that delivers solutions for coronary artery bypass graft (CABG) surgery.
Its product portfolio includes DuraGraft, a vascular graft storage and flushing solution; and Krillase, an enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi.
The company also engages in the development of MAR-FG-001, a fat grafting technology for fat grafting procedures.
Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018.
The company was incorporated in 2007 and is based in Jupiter, Florida.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | David Barthel |
Contact Details
Address: 555 Heritage Drive Jupiter, Nevada 33458 United States | |
| Phone | 561 935 9955 |
| Website | marizyme.com |
Stock Details
| Ticker Symbol | MRZM |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US5703721028 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David L. Barthel M.B.A. | Chief Executive Officer, Secretary and Director |
| George Kovalyov C.A., CPA | Chief Financial Officer, Treasurer and Director |
| Dr. Catherine J. Pachuk Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Steven Scott Brooks FACC, M.B.A., M.D. | Chief Medical Officer |
| Dr. Claudio Rigatto M.D. | Chief Medical Officer of My Health Logic |
| Kari Jacobson | Controller |
| Harrison Albert Ross C.F.A. | Vice President of Finance |